The present invention relates to the adenosine A3 receptor ligands of the generalformula (I), within them favourably to the antagonists, to their salts, solvates,-oxides and isomers, to the pharmaceutical compositions containingthe compounds of the general formula (I), their salts, solvates, -oxidesand isomers, to the use of the compounds of the general formula (I), their salts,solvates, -oxides and isomers, to the preparation of the compoundsof the general formula (I), their salts, solvates, -oxides and isomers,as well as to the new intermediates of the general formula (II), (VI), (XI), (XII)and (XV), and to the preparation thereof.
